+0.37%
Today
Loading 1D prices…
Company profile
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
NYSE
Display currency
USD
Location
Laval, QC, United States
Employees
20.3K
Fiscal year end
1231
CIK
885590
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| URGNUroGen Pharma Ltd. Ordinary Shares | $2.1B | $109.8M | -139.81% | -$3.19 | +3.07% | Buy |
| TRVITrevi Therapeutics Inc. Common Stock | $2.1B | $0.00 | — | -$0.32 | -4.34% | Buy |
| ZBIOZenas BioPharma Inc. Common Stock | $2.1B | $10M | -3777.37% | -$8.44 | +1.39% | Buy |
| OCULOcular Therapeutix Inc. Common Stock | $2.2B | $52M | -511.90% | -$1.42 | -5.46% | Buy |
| SRPTSarepta Therapeutics Inc. Common Stock (DE) | $2.1B | $1.9B | -38.27% | -$7.13 | -0.29% | Hold |